Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
BeiGene, Ltd. - American Depositary Shares
(NQ:
BGNE
)
184.71
UNCHANGED
Last Price
Updated: 4:00 PM EST, Dec 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about BeiGene, Ltd. - American Depositary Shares
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress
May 12, 2022
From
BeiGene
Via
Business Wire
52 Stocks Moving In Wednesday's Mid-Day Session
↗
May 11, 2022
Gainers Trecora Resources (NYSE: TREC) shares jumped 26.6% to $9.56 as the company agreed to be acquired by an affiliate of Balmoral Funds at $9.81 per share in cash or an enterprise value of $247...
Via
Benzinga
Where BeiGene Stands With Analysts
↗
May 09, 2022
Within the last quarter, BeiGene (NASDAQ:BGNE) has observed the following analyst ratings:
Via
Benzinga
Novartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer Trial
↗
April 27, 2022
Via
Benzinga
BeiGene Shares Updated Data From Tislelizumab Combo Trial In Head & Neck Cancer
↗
April 19, 2022
Via
Benzinga
99 Biggest Movers From Yesterday
↗
May 12, 2022
Gainers Armstrong Flooring, Inc. (NYSE: AFI) shares jumped 237% to settle at $0.49 on Wednesday after a 13D filing showed Esopus Creek Advisors LLC disclosed a 5.1% active stake in the company.
Via
Benzinga
Week in Review: VectorBuilder Plans $500 Million Gene Therapy Delivery CDMO in Guangzhou
↗
April 16, 2022
Deals, financings, trials and approvals in biotech in China this week.
Via
Talk Markets
Why Roche's Flop In Lung Cancer Hammered Arcus, Iteos And Others
↗
May 11, 2022
Roche isn't the only company working on an anti-TIGIT molecule.
Via
Investor's Business Daily
34 Stocks Moving in Wednesday's Pre-Market Session
↗
May 11, 2022
Gainers Embark Technology, Inc. (NASDAQ: EMBK) rose 36.4% to $1.95 in pre-market trading. Embark Technology posted a Q1 loss of $0.04 per share.
Via
Benzinga
Week In Review: OrbiMed Plans To Raise $1.1 Billion For Fifth Asia Fund
↗
May 07, 2022
One year after raising $3.5 billion for three funds in 2021, OrbiMed, the world’s largest healthcare-dedicated investor, is back with plans for $4.75 billion in new funds despite the slowdown in...
Via
Talk Markets
Recap: BeiGene Q1 Earnings
↗
May 05, 2022
BeiGene (NASDAQ:BGNE) reported its Q1 earnings results on Thursday, May 5, 2022. Here's what investors need to know about the announcement. Earnings BeiGene beat estimated earnings by 10.36%, reporting...
Via
Benzinga
HFCAA News: 128 Chinese Stocks the SEC Could Delist
↗
May 05, 2022
The SEC has released a massive list of Chinese stocks that could face delisting on Holding Foreign Companies Accountable Act news.
Via
InvestorPlace
BeiGene Reports First Quarter 2022 Financial Results
May 05, 2022
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
May 04, 2022
From
BeiGene
Via
Business Wire
BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton West Innovation Campus in New Jersey
April 29, 2022
From
BeiGene
Via
Business Wire
BeiGene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Waldenström’s Macroglobulinemia
April 28, 2022
From
BeiGene
Via
Business Wire
BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual Meeting
April 27, 2022
From
BeiGene
Via
Business Wire
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
↗
April 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Global Phase 3 Trial of BeiGene’s PD-1 Inhibitor, Tislelizumab, in Combination with Chemotherapy Meets Primary Endpoint in First-Line Advanced Esophageal Squamous Cell Carcinoma
April 27, 2022
From
BeiGene
Via
Business Wire
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
↗
April 26, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
BeiGene Introduces Global Environmental, Social, and Governance Strategy
April 26, 2022
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Provides Grant to Crossroads4Hope to Fund Psychosocial Support Programs for Cancer Patients and Communities in New Jersey
April 21, 2022
From
BeiGene
Via
Business Wire
InnoCare Pharma Goes Back to Funding Trough With STAR Market Listing
↗
April 19, 2022
Key Takeaways: InnoCare Pharma’s A-share IPO will make it the fourth innovative pharma company with shares traded in Hong Kong and on the mainland’s STAR Market...
Via
Benzinga
BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tislelizumab in First-Line RM-NPC in Virtual ASCO Plenary Series
April 19, 2022
From
BeiGene
Via
Business Wire
China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma
April 15, 2022
From
BeiGene
Via
Business Wire
BeiGene's Brukinsa Tops JNJ's Imbruvica In Overall Response Rate In Leukemia Study
↗
April 11, 2022
BeiGene Ltd (NASDAQ: BGNE) has announced results from the Phase 3 ALPINE trial of Brukinsa (zanubrutinib) in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic...
Via
Benzinga
Cancer Drug Maker BeiGene Takes Action to Mitigate Delisting Risk
↗
April 11, 2022
Key Takeaways: BeiGene has switched auditors for its New York listing to a U.S. company from a Chinese one in a move to comply with U.S. law The change could reduce the company...
Via
Benzinga
IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia
April 11, 2022
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors at the AACR Annual Meeting 2022
April 08, 2022
From
BeiGene
Via
Business Wire
The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
↗
April 06, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
